Clinical Trials Browser

Phase 1/2 × NIH × Urogenital Neoplasms × Clear all

NCT03480152 2020-06-02

Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous Cancer

Phase 1/2 Terminated

5 enrolled 11 charts

DermatologicGastrointestinal

Colonic Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Urogenital Neoplasms